Pappas Introduces Drug Deal Disclosure Act to Force Transparency for Trump's Secret Big Pharma Deals

July 15, 2026 Press Release Today Congressman Chris Pappas (NH-01) joined Congresswoman Judy Chu (CA-28), Congresswoman Kathy Castor (FL-14), and Congresswoman Summer Lee (PA-12) in introducing the Drug Deal Disclosure Act , legislation that would require the Trump administration to publicly disclose its prescription drug pricing agreements with pharmaceutical manufacturers and subject those agreements to independent review to determine whether they are actually lowering costs for patients and taxpayers. As Americans continue to struggle with the high cost of prescription drugs, the Trump administration has repeatedly claimed that a series of agreements negotiated with pharmaceutical companies will lower costs for patients. Yet despite public announcements and White House events promoting these arrangements, the Administration has refused to disclose the terms of the agreements, the concessions offered in exchange, and evidence that they will actually deliver lower prices. “Deals made by the White House are the business of the American people. President Trump claims to have made secret agreements with Big Pharma CEOs under the pretense of lowering prescription drug prices but these savings have yet to appear. The American people deserve answers and this legislation will bring them to light,” said Congressman Pappas. “Granite Staters are paying too much for life-saving prescription drugs and this administration and Republicans in Congress have only made health care access worse and costs higher. I remain committed to doing everything I can to improve care and lower costs, and I will not stand for shady deals and false promises made by the administration.” The Drug Deal Disclosure Act would require the Department of Health and Human Services (HHS) to publicly disclose records, communications, agreements, and related materials concerning drug pricing agreements and other arrangements negotiated between the Trump Administration and pharmaceutical manufacturers. The bill would also require reporting to Congress and direct the Congressional Budget Office (CBO) and Government Accountability Office (GAO) to conduct an independent analysis of the agreements' economic and budgetary impacts. Specifically, the legislation would: Require HHS to publicly disclose agreements, communications, records, and related materials concerning covered agreements between the Trump Administration and pharmaceutical manufacturers; Require disclosure of agreements involving Most-Favored-Nation pricing commitments, TrumpRx participation, tariff exemptions, domestic investment commitments, Strategic National Stockpile agreements, Priority Review Vouchers, and other related arrangements; Require HHS to report to Congress on all documents and information released or withheld, including the basis for any redactions; and Direct CBO and GAO to publish an independent assessment of the agreements' impacts on patients, taxpayers, prescription drug costs, Medicare, Medicaid, competition, and federal spending. The Drug Deal Disclosure Act is the House companion to legislation introduced in the Senate by Senate Finance Committee Ranking Member Ron Wyden, Senator Maggie Hassan, and Senate Democrats. Issues : Health Care